| The Safety and PK Characteristics of the Co-administration of JLP-2002 and Comparator in Healthy Volunteers (NCT04914221) | Jeil Pharmaceutical Co., Ltd. | 2021-03-13 |
| A Study With Mirabegron 50 mg and 25 mg in Chinese Participants With Overactive Bladder (NCT04562090) | Astellas Pharma China, Inc. | 2021-01-06 |
| Open Label Study to Evaluate the Efficacy of the Home Based Electrical Transcutaneous URIS I in the Treatment of Overactive Bladder (OAB). (NCT05211193) | Stimvia s.r.o. | 2020-01-08 |
| Treatment Persistence Among Patients With Overactive Bladder: A Retrospective Secondary Data Analysis in Asia Oceania (NCT03602508) | Astellas Pharma Singapore Pte. Ltd. | 2018-07-20 |
| A Registry Study of Patients Initiating a Course of Drug Therapy for Overactive Bladder in Taiwan, Korea and China (NCT03572231) | Astellas Pharma Singapore Pte. Ltd. | 2018-07-19 |
| Vaginal CO2 Laser in Postmenopausal Women With Overactive Bladder Syndrome (OAB) (NCT03846895) | National and Kapodistrian University of Athens | 2018-05-12 |
| PTNS vs Botox of Refractory OAB (NCT04451382) | Medstar Health Research Institute | 2015-03-01 |
| Postmarketing Study to Evaluate add-on Therapy With Anticholinergics in Patients With Overactive Bladder (OAB) on Mirabegron. (NCT02294396) | Astellas Pharma Inc | 2014-10-28 |
| Study to Evaluate the Efficacy, Safety, and Tolerability of Mirabegron in Older Adult Subjects With Overactive Bladder (OAB) (NCT02216214) | Astellas Pharma Global Development, Inc. | 2014-10-07 |
| A Study to Evaluate Tolerability and Participants Preference Between Mirabegron and Tolterodine Extended Release (ER) in Participants With Overactive Bladder (OAB) (NCT02138747) | Astellas Pharma Global Development, Inc. | 2014-07-24 |
| Drug Use Investigation for Toviaz (NCT01936870) | Pfizer | 2013-10-01 |
| Vesitirimâ„¢ in Men Postmarketing Observational Study (NCT01639794) | Astellas Pharma Europe Ltd. | 2012-02-01 |
| SVT-40776 in Patients Suffering From Overactive Bladder Syndrome (NCT00507169) | Salvat | 2006-09-01 |
| Patient's Perception of Treatment Outcome With Darifenacin by Patients With Overactive Bladder (NCT00366002) | Novartis | 2006-06-01 |
| Detrol LA In Men With Overactive Bladder. (NCT00282932) | Pfizer's Upjohn has merged with Mylan to form Viatris Inc. | 2006-01-01 |
| A Study Measuring and Tracking Changes in Overactive Bladder (OAB) Medication (NCT01317810) | Astellas Pharma Inc | |
| A Phase II Study of KUC-7483 in Patients With Overactive Bladder (NCT00742833) | Kissei Pharmaceutical Co., Ltd. | |